Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
Given the newer ATA guidelines, what is your approach to the management of Hurthle cell carcinoma?
Related Questions
In which specific scenarios would you consider transitioning from oral to intravenous thyroid hormone replacement in the outpatient setting?
Is there a role for increasing dietary vitamin E in patients at risk for developing autoimmune thyroiditis?
Statistically speaking, approximately what percentage of thyroid nodule FNA biopsies are Bethesda category 1 (= nondiagnostic or unsatisfactory), and what percentage are indeterminate (Bethesda category 3 and 4)?
How do you counsel patients that are positive for both stimulatory and inhibitory autoimmune thyroid markers (TRAb, TSI and TPO Ab) regarding their likelihood of flipping from hyperthyroidism to hypothyroidism?
How far in advance of a nuclear medicine thyroid update and scan should thionamides be discontinued and does this duration vary based on radio-isotope used (i.e. technetium versus RAI 123)?
How do you counsel patients with elevated Thyroglobulin Peroxidase antibody levels, diffuse thyroiditis features on ultrasound, non-specific symptoms of fatigue, but normal biochemical thyroid function labs?
Should a different weight-based dosing algorithm for levothyroxine therapy be considered in women versus men given higher incidence of iatrogenic thyrotoxicosis in women?
Are there specific populations with hypothyroidism for whom you would consider adding liothyronine to levothyroxine therapy, given observational data linking levothyroxine therapy alone to higher risks of dementia and mortality?
How do you approach treatment of depression in Graves' Disease?
Are thyroid molecular tests (such as Afirma, ThyroSeq) validated for use on FNA thyroid nodule samples that are not Bethesda class 3-4?
